Boundless Bio, Inc. (BOLD)
NASDAQ: BOLD · Real-Time Price · USD
1.440
-0.010 (-0.69%)
Jun 1, 2026, 4:00 PM EDT - Market closed
Boundless Bio Employees
Boundless Bio had 28 employees as of December 31, 2025. The number of employees decreased by 36 or -56.25% compared to the previous year.
Employees
28
Change (1Y)
-36
Growth (1Y)
-56.25%
Revenue / Employee
n/a
Profits / Employee
-$1,999,786
Market Cap
32.28M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 28 | -36 | -56.25% |
| Dec 31, 2024 | 64 | -8 | -11.11% |
| Mar 31, 2024 | 72 | 0 | - |
| Dec 31, 2023 | 72 | - | - |
| Sep 30, 2023 | 71 | - | - |
| Jun 30, 2023 | 72 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 82 |
| Evaxion | 46 |
| Senti Biosciences Holdings | 39 |
| Daré Bioscience | 24 |
| ABVC BioPharma | 19 |
| Tevogen Bio Holdings | 18 |
| Apollomics | 14 |
| Tvardi Therapeutics | 12 |
BOLD News
- 24 days ago - Boundless Bio reports Q1 EPS (60c), consensus (56c) - TheFly
- 24 days ago - Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights - GlobeNewsWire
- 24 days ago - Boundless Bio Quarterly report: Q1 2026 - Filings
- 24 days ago - Boundless Bio Earnings release: Q1 2026 - Filings
- 24 days ago - Boundless Bio Slides: Corporate presentation - Filings
- 4 weeks ago - Boundless Bio Proxy statement: Proxy filing - Filings
- 4 weeks ago - Boundless Bio Proxy statement: Proxy filing - Filings
- 6 weeks ago - Boundless Bio presents preclinical data for BBI-940 therapy at AACR - TheFly